您现在的位置: 首页> 研究主题> 部分性脾栓塞

部分性脾栓塞

部分性脾栓塞的相关文献在1995年到2022年内共计66篇,主要集中在内科学、外科学、肿瘤学 等领域,其中期刊论文62篇、会议论文4篇、专利文献457031篇;相关期刊52种,包括甘肃科技、医药与保健、中国社区医师(医学专业)等; 相关会议4种,包括第十三届全国医学影像学学术研讨会、全军第十二次影像学年会暨全军第十一次影像技术学年会、福建省早期肺癌影像诊断学术研讨会、第九次全国中西医结合影像学术交流大会等;部分性脾栓塞的相关文献由172位作者贡献,包括何乾文、李建浩、顾明等。

部分性脾栓塞—发文量

期刊论文>

论文:62 占比:0.01%

会议论文>

论文:4 占比:0.00%

专利文献>

论文:457031 占比:99.99%

总计:457097篇

部分性脾栓塞—发文趋势图

部分性脾栓塞

-研究学者

  • 何乾文
  • 李建浩
  • 顾明
  • 党建波
  • 凡生
  • 刘东华
  • 刘忠民
  • 刘明军
  • 周伟生
  • 孙刚
  • 期刊论文
  • 会议论文
  • 专利文献

搜索

排序:

年份

    • 吴金棉; 罗骏阳; 梁炎辉; 陈大娟
    • 摘要: 目的:探讨部分性脾栓塞(PSE)联合普萘洛尔对门脉血流动力学的影响在肝硬化门脉高压并食管胃底静脉曲张患者中的应用效果。方法:选取确诊的肝硬化门脉高压并食管胃底静脉曲张患者76例为研究对象,随机分为三组,对照A组25例采用PSE治疗,对照B组25例采用普萘洛尔治疗,联合组26例采用PSE加普萘洛尔治疗。比较三组治疗前后门脉血流动力学、脾静脉血流动力学、炎性反应因子水平、食管静脉曲张破裂出血发生率。结果:治疗1周、治疗1个月联合组门静脉流速、门静脉内径、门脉压力、脾静脉流速、脾静脉血流量低于对照A组、对照B组,治疗1周对照A组门静脉流速、门静脉内径、门脉压力、脾静脉流速、脾静脉血流量低于对照B组(P0.05)。结论:PSE联合普萘洛尔治疗肝硬化门脉高压并食管胃底静脉曲张,可有效改善患者门脉、脾静脉血流动力学,减轻炎性反应。
    • 卢雄; 张欢; 李海庆
    • 摘要: 部分性脾栓塞术(Partial SplenicEmbolization,PSE)主要适用于肝硬化门静脉高压所致脾脏功能亢进,还应用于地中海贫血、遗传性红细胞增多症、特发性血小板减少性紫癜等血液病患者,是目前治疗肝硬化失代偿期脾亢的首选治疗方法.本文就PSE术后不良反应(肺炎、上消化道出血、脾脓肿、脾坏死、顽固性腹水、胸腔积液、肠梗阻、胰腺炎)的起因及应对措施作一综述.
    • 魏涛; 马海庆; 池永娥
    • 摘要: 目的:研究肝动脉化疗栓塞(TACE)联合部分性脾栓塞(PSE)治疗伴脾亢肝癌的临床治疗效果。方法选取2013年2月-2014年2月本院诊治的64例原发性肝癌患者,按照患者病情分为两组,对照组32例患者为单纯性肝癌行TACE治疗,研究组32例患者为肝癌合并脾亢行TACE联合PSE治疗,分析两组患者治疗后的临床指标及肝功能情况。结果研究组治疗后PLT、WBC指标术后明显增多,对照组患者术后ALT、AST明显高于研究组,比较差异具有统计学意义(P<0.05)。结论肝动脉化疗栓塞(TACE)联合部分性脾栓塞(PSE)治疗伴脾亢肝癌的临床治疗效果显著,缓解肝功能损伤情况。
    • 姜政伟; 王东清
    • 摘要: 目的:探讨肝动脉化疗栓塞(TACE)联合部分性脾栓塞(PSE)治疗肝癌伴门静脉癌栓的临床疗效及可行性。方法2013年1月~2013年10月在临床上诊断为肝癌伴门静脉癌栓患者20例,治疗组接受TACEA及PSE联合治疗,对照组单纯接受TACE治疗。结果对照组3个月、6个月、9个月生存率分别为50%(4/10)、30%(3/10)、10%(1/10),最长生存时间为9个月。治疗组3个月、6个月、9个月生存率分别为60%(6/10)、40%(4/10)、30%(3/10),最长生存时间为13个月。结论在肝癌伴门静脉癌栓患者中,采用肝动脉化疗栓塞(TACE)联合部分性脾栓塞治疗可以降低门静脉高压并发症发生率。%Objective To evaluate the clinical curative effect and feasibility of the hepatic arterial chemo embolization (conventional) combined therapy with partial splenic embolization (PSE) in the portal venous tumor emboli. Methods In January 2013~October 2013, 20 patients with hepatocellular carcinoma (HCC) with portal venous tumor emboli, the treatment group received TACEA and PSE combination therapy, the control group treated with conventional TACE alone. Results The control group for 3 months, 6 months, 9 months survival rates were 50%(4/10), 30%(3/10), 10%(1/10), the longest survival time for nine months. Treatment group 3 months, 6 months, 9 months survival rates were 60%(6/10), 40%(4/10), 30%(3/10), the longest survival time for 13 months. Conclusion For patients with hepatocellular carcinoma (HCC) with portal venous tumor emboli, effective relief of the portal hypertension complications, high feasibility, etc.
    • 王晓建
    • 摘要: 目的:探讨部分性脾栓塞术治疗肝硬化脾功能亢进的疗效。方法经股动脉行超选择性脾动脉插管,造影并分析脾动脉分支及胰腺、胃分支情况。然后应用明胶海绵颗粒进行脾动脉栓塞术。结果32例脾亢病人均收到良好的疗效,脾下极动脉栓塞组较脾动脉主干栓塞组术后反应轻微。结论部分性脾栓塞是治疗脾功能亢进安全有效的方法;既可保留脾脏的免疫功能,又能有效控制脾功能亢进症状;部分性脾动脉栓塞可作为肝硬化脾功能亢进的首选治疗方法,脾下极动脉栓塞在收到良好疗效的同时可使术后反应有所减轻。%Objective To investigate the effect of partial splenic embolization in the treatment of hypersplenism in hepatic cirrhosis. Methods The splenic artery catheterization was performed by the femoral artery and made a radiography.The branch of splenic artery and the branch of pancreas and stomach were analyzed.Then the splenic artery embolization with gelatin sponge particles was per-formed. Results 32 cases of hypersplenism patients have received good curative effect,the splenic artery embolization group was slightly less than that of the splenic artery trunk embolization group. Conclusion Partial splenic embolization is a safe and effective method for the treatment of splenic function.It can retain the immune function of spleen, and can effectively control the symptoms of spleen.Partial splenic arterial embolization can be used as the ifrst choice for the treatment of liver cirrhosis and spleen. The splenic embolization can not only get good effect ,but also reduce the postoperative reaction.
    • 路萍; 宫喜翔; 王永志; 朱桂华
    • 摘要: Objective To observe the clinical effect of partial plenic embolization (PSE) for refractory idiopathic thrombocytopenic purpure (RITP). Method 16 patients with RITP received PSE after failure of internal medicine theray, then the effects of PSE were evaluated. Results The number of blood platlets was improved significantly after operation in all cases, the short- period effective rate of PSE was 100% , the short- term effective rate was 87.6% and the long-term effective rate was 75.0% . Conclusions PSE has similar effects to resection of the spleen, at the same time, PSE reserves a part of spleen and spleen's immunity function, its curative effects show no significant differences with splenectomy. It is a safe and simple method to treat RITP.%目的 探讨部分脾栓塞(PSE)治疗难治性原发血小板减少性紫癜(RITP)的临床疗效.方法 对16例经内科治疗无效的RITP患者行PSE术治疗后的临床资料进行回顾性分析.结果 16例RITP患者PSE术后血小板均较术前发生了显著改变.PSE治疗RITP短期有效率100%,近期总有效率87.6%,远期总有效率75.0%.结论 PSE达到了与切除脾脏相似的效果,同时保留了部分脾组织,使其免疫功能得以保存,其疗效与脾切除无湿著性差异,是一种治疗RITP安全、简便的手段.
    • 林志强; 郭荣平; 俞武生; 卢春丽; 卢焕全; 胡夏荣; 吴志明; 尹永硕; 王在国; 韦玮
    • 摘要: 目的 探讨不同方法 治疗肝癌合并脾功能亢进患者的临床疗效和意义.方法 回顾性分析2007~2010年收治的63例肝癌合并脾功能亢进患者的临床资料,其中,26例行单纯肝癌切除术(Ⅰ组),18例行肝切除同时联合脾切除或脾动脉结扎(Ⅱ组),19例行术前部分性脾栓塞(partial splenic embolization,PSE)联合肝切除(Ⅲ组).观察3组治疗前后外周血细胞变化情况,分析围术期出血、输血和并发症等情况,比较各组1、3年总生存率.结果 联合手术组术后外周血白细胞、血小板均较单纯手术组明显改善,与术前PSE组无明显差异.术前PSE组患者出血量和输血量均较Ⅱ组和Ⅰ组明显减少(P < 0.05).联合手术组和术前PSE组的术后并发症明显低于单纯手术组患者,Ⅰ、Ⅱ和Ⅲ组患者1、3年总生存率分别为:68.5%、38.1%,82.8%、52.6%和85.5%、56.3%,Ⅰ组患者显著低于Ⅱ组和Ⅲ组(P < 0.05).结论 肝脾联合手术和术前PSE是治疗肝癌合并脾功能亢进安全、有效的方法.术前PSE治疗更适合严重的门脉高压、巨脾、老龄和体质差患者.
    • 李曙晖; 盖伟; 靳西凤; 崔梅; 柴同海; 刘春安
    • 摘要: 目的 探讨应用TH胶栓塞联合门体静脉小分流治疗门脉高压食管胃底曲张静脉曲张破裂出血中的应用价值.方法 入选41例门静脉高压症并食管胃底静脉曲张的患者,其中21例行TH胶栓塞联合门体静脉小分流术(A组),另外20例患者行经皮经肝食管胃底曲张静脉栓塞术(PTVE)联合部分性脾栓塞(PSE)(B组),对比两组患者肝功能、白细胞、血小板改变、食管胃底曲张静脉消失率、再出血率、肝性脑病发生率及门静脉自由压(free portal pressure,FPP)变化.结果 A组曲张静脉消失率、总有效率均高于B组(P<0.05),再出血率、肝性脑病发生率均低于B组(P<0.05),术后门静脉压力亦明显低于B组(P<0.01).两组术后白细胞及血小板、白蛋白较术前明显升高,差异有统计学意义(P<0.01),两组之间也存在显著统计学差异(P<0.01).结论 以TH胶栓塞联合门体静脉小分流治疗门静脉高压症食管胃底静脉曲张安全、有效、并发症少,值得临床应用与推广.%Objective To explore the clinical efficacy of fixed TH glue (a cyanoacrylate) embolization combined with TIPS in the treatment of portal hypertension combined with gastroesophageal varices bleeding. Methods A total of 41 cases of portal hypertension combined with gastroesophageal varices bleeding were divided into two groups: 21 patients treated with TH glue embolization combined with transjugular intrahepatic Portosystemic shunt (TIPS) (group A)and 20 patients treated with percutaneous transhepatic variceal embolization (PTVE) combined with partial splenic embolization (PSE) ( group B). The incidence of rebleeding, disappearance rate of esophageal variceal, the improvement of splenemagly and the occurring rate of hepatic encephalopathy were observed in two groups. Free portal pressure (FPP) in pre- and post-treatment were measured in all cases. Results All procedures and operations were successful.The rate of variceal disappearance and the total effective rate were significantly higher in group A than those in group B.The recurrent bleeding rate and the incidence of hepatic encephalopathy were lower in group A than those in group B ( P < 0.05 ). And the statistical difference was observed in FPP in the two groups before and after therapy ( P < 0. 01 ).The number of white blood cells and platelet were obviously improved after treatment in the two groups ( P < 0.01 ).Conclusion Percutaneous transhepatic fixed TH glue embolization combined with TIPS is safe, reasonable and effective in the treatment of portal hypertension combined with gastroesophageal varices.
    • 曹澍; 凡生; 张林波
    • 摘要: 目的:探讨部分性脾栓塞(PSE)治疗脾亢的术后并发症及其预防、处理.方法:45例各种原因所致的脾亢患者,采用Seldinger技术,用明胶海绵颗粒或/和明胶海绵条行PSE.结果:技术成功率100%,术后发热、腹痛45例,恶心、呕吐40例,肝功损害加重5例,肝功一过性损害20例.栓塞面积40%~60%35例,8例出现少量胸水,2例少量胸水伴左下肺炎,栓塞面积60%以上10例,2例出现较严重的并发症.结论:PSE治疗脾功能充进安全、疗效肯定,术后并发症常见,经一般对症处理好转;只要病例选择适当,栓塞面积恰当,产重并发症少见.
    • 李洪波; 丁大明; 党建波; 孙刚; 胡元清; 王亚伟
    • 摘要: 目的 研究部分性脾栓塞用于治疗肝硬化脾功亢进所致的血液系统疾病的临床意义.方法 在透视监视下,经股动脉应用 Seldinger 技术插管行脾动脉造影后,选择适当的栓塞材料行"外壳式"栓塞脾动脉.结果 当栓塞范围控制在60%~80%,临床有效率达90%以上,无1例发生严重并发症.结论 应用此介入疗法能够保留部分脾脏以完成其免疫功能,同时又有效的改善了因脾脏功能亢进引起的外周血像改变.该治疗方法 并发症低,可以成为脾切除治疗脾功亢的替代疗法.
  • 查看更多

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号